Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Evgeniy EvdoshenkoAlexandra StepanovaMaria ShumilinaMaria DavydovskayaNatalia KhachanovaNikolay NeofidovIvan KalininEkaterina PopovaEkaterina DubchenkoNatalia PozhidaevaAndrey VolkovStella SivertsevaAnna PrilenskayaNadezhda MalkovaDenis KorobkoIlona VergunovaSergey ShchurGleb Makshakov

Published in: PloS one (2019)

Natalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation.

Keyphrases

multiple sclerosis
clinical practice
end stage renal disease
white matter
newly diagnosed
ejection fraction
primary care
healthcare
quality improvement
peritoneal dialysis
prognostic factors
patient reported outcomes
combination therapy